<DOC>
	<DOCNO>NCT00122772</DOCNO>
	<brief_summary>The purpose trial study clinical effect two/four high dose rate ( HDR ) brachytherapy application teletherapy without weekly cisplatin cervix cancer .</brief_summary>
	<brief_title>CRP Radiobiological Clinical Studies Viral-Induced Cancer 's Response Radiotherapy</brief_title>
	<detailed_description>This study use 2x2 design test external beam radiotherapy ( 46 Gy 23 daily fraction ) without HDR brachytherapy ( 2 fraction 9 Gy versus 4 fraction 7 Gy ) without weekly Cisplatin ( 40 mg/sqm ) The overall objective test clinical outcome toxicity resource-sparing schedule radiotherapy without chemotherapy treatment cervix cancer , detect molecular marker predict tumor control/resistance establish whether E6 E7 viral protein predict cellular radiosensitivity oxic hypoxic condition vitro tumor control/resistance vivo . A new component CRP add , objective optimize data capture , provide detail normal tissue outcome follow cancer treatment develop country validate approach use patient participate ongoing CRP . This achieve explore data capture use questionnaire template computer face-to-face interview ( `` active '' data collection ) compare standard data collection obtain clinical note ( `` passive '' data collection ) still ongoing CRP E3.30.24 . The method data collection choose random case stratify centre . The reason use ongoing CRP test usefulness new method validate multicentre study . During performance new CRP , institution E3.30.24 engage .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically confirm cervix cancer . FIGO stage IIB IIIB Age 18 year Karnofsky status &gt; /= 50 No significant medical contraindication administration full dose chemotherapy . Adequate bone marrow function Haemoglobin ³ 10 g/dl without transfusion , white blood count ³ 4000/mL , platelet count ³ 140,000/mL . Adequate renal function : creatinine &lt; 1.2 mg/dL 120 μmol/l ( urinary diversion permit ) . Electrolytes calcium within normal limit institution . Liver function test clinically indicate . Tests obtain within 30 day registration . Expected good compliance followup . Written inform consent participation study . EXCLUSION CRITERIA : Recent malignancy , index cervical carcinoma nonmelanoma cutaneous cancer , diagnose within 5 year entry Life expectancy &lt; 6 month , reason index cervical carcinoma Any severe medical ailment , continue pregnancy , breast feeding , condition interfere present treatment Previous chemotherapy past 1 year Severe psychiatric disorder , make compliance followup difficult . Paraaortic node ( PAN &gt; 1 cm ) , suspicious positive metastatic involvement radiological imaging . ( Note : patient positive pelvic lymph node still eligible study , suspicious positive PAN . ) Bilateral hydronephrosis Prior radiation pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>